PROCEPT BioRobotics Corporation (PRCT)

NASDAQ • Healthcare

$20.38

+$0.3 (+1.5%)

Market closed

Last close at September 11, 2026 at 20:00 UTC

Open$20.23

Day Range$19.55 - $20.67

Avg. Volume (3M)1M

Market Cap$1.1B

52 Week Range

$16.67$40.1

Next EarningsIn 51 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$94.4M100%

Gross Profitminus cost of goods$62.3M66%

In plain terms: out of every $100 in revenue, PROCEPT BioRobotics Corporation currently loses $28.

Fundamentals & Financials

Revenue (TTM)

$337.3M

Net Income (TTM)

-$109.7M

EPS (TTM)

-$1.94

ROA (TTM)

-22.9%

Current Ratio

6.55

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+14.6%Q3 2025-$0.35

+7.3%Q4 2025-$0.38

-65.6%Q1 2026-$0.53

-1.8%Q2 2026-$0.56

-1.8%Q3 2026-$0.47

Nov 3

in 51 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -1.8%

PROCEPT BioRobotics’ revenue topped consensus in the second fiscal quarter of 2026, even as EPS trailed, in results reported August 4, 2026. Revenue rose 19.3% to roughly $94.5 million, up from $79.2 million a year ago, and came in at $94.5 million versus a $92.8 million estimate, +1.9%. Gross profit was about $62.4 million, with gross margin at 66.0%, while operating income was -$27.4 million and operating margin stood at -29.0%. Net income was -$26.9 million, down 37.2% from -$19.6 million a year ago, and EPS was -$0.47 versus -$0.35 a year ago; on the consensus tape, EPS of -$0.47 trailed the -$0.46 estimate (difference -$0.01). The quarter also included negative operating cash flow of roughly $57.4 million. For the next period, consensus calls for EPS of -$0.39 on revenue of $101.1 million.

View full earnings history

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) makes urology-focused medical devices built around robotic treatment for benign prostatic hyperplasia, centered on the AquaBeam Robotic System and Aquablation therapy. The company generated $308.1 million of revenue in FY2025. Its business sits in healthcare, where it develops and sells surgical technology for minimally invasive procedures.

Name

PROCEPT BioRobotics Corporation

CEO

Larry L. Wood

Website

www.procept-biorobotics.com

Industry

Healthcare

Year Founded

2007

Employees

888

Today's Snapshot

AI-generated

PRCT closed 1.5% above yesterday's close, while its sector was flat. Shareholders’ lawyers pursued a securities-fraud class action against PROCEPT over alleged undisclosed inventory issues.

Trading Volume

Above 10d avg 1.1M

1.4M

vs S&P 500 Today

Outperforming Market

+0.61%

Updated: September 11, 2026 at 20:07 UTC

Technical Indicators

1 Buy2 Neutral5 Sell

PRCT presents a neutral technical picture with the price near $20.38 sitting around the classic pivot at $20.16 and beneath most longer-term averages, though it is marginally above the 50‑day level. Momentum is mixed — RSI just below neutral and a deeply negative CCI offset by a rising stochastic — while ADX under 20 indicates little established trend. Volatility is elevated with an ATR near $1.20 and on‑balance volume is negative, suggesting limited conviction. Overall the indicators point to a neutral stance. Technical takeaway: Neutral.

All signals